Targeting the HGF/Met signalling pathway in cancer
- 22 March 2010
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 46 (7) , 1260-1270
- https://doi.org/10.1016/j.ejca.2010.02.028
Abstract
No abstract availableKeywords
This publication has 110 references indexed in Scilit:
- Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancerBMC Cancer, 2009
- The MET axis as a therapeutic targetUpdate on Cancer Therapeutics, 2009
- A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical SettingsApplied Immunohistochemistry & Molecular Morphology, 2009
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal CarcinomaJournal of Clinical Oncology, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonistProceedings of the National Academy of Sciences, 2007
- From Tpr-Met to Met, tumorigenesis and tubesOncogene, 2007
- Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivoCurrent Biology, 1998